N/A N=60 Randomized Double-blind Treatment

Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy

Marijuana Use · Pregnancy

Bottom Line

View on ClinicalTrials.gov: NCT02191605 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2018

Primary outcome: Primary: Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery — 6; 7; 6; 3 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: eSBIRT (Behavioral); Tailored texting (Behavioral)
Age: Adult · 18+ yrs
Sex: Female
Sponsor: Wayne State University
Primary completion: Apr 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery	6; 7; 6; 3; 2	—
PRIMARY Number of Participants Abstinent From Marijuana for the 90 Days Prior to Delivery	2; 5; 1; 2; 2	—

Summary

Marijuana is by far the mostly commonly used illicit drug during pregnancy, and prenatal exposure to marijuana can have lasting negative effects. However, current answers to this problem are failing to reach most women who use marijuana while pregnant. This project will develop and begin testing two technology-based, highly practical interventions that could reduce the number of children who are prenatally exposed to marijuana.

Eligibility Criteria

Inclusion Criteria

18 to 40 years of age
20 weeks or less gestation
intention to carry pregnancy to term
self-reported marijuana use in month before pregnancy
own a cell phone and willingness to receive text messages
gives consent to access medical records for collection of birth outcome data

Exclusion Criteria

frank cognitive impairment or psychosis
not able to communicate in English
not planning to deliver at a Detroit Medical Center (DMC) hospital
previous or current participant in a study conducted by Dr. Ondersma
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Perinatal Research Branch participant.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02191605). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.